Brazilian researchers have created a functional bread using the probiotic yeast Saccharomyces cerevisiae UFMG A-905, which has shown potential in preventing asthma symptoms in mice. The bread formulation, now patented, demonstrated reduced airway inflammation and asthma biomarkers in the test subjects. Although further human trials are required, the research team is optimistic about the bread’s potential as a widely consumable, natural food product to help manage asthma.
Bread made with probiotic yeast showed promising results in mouse experiments, indicating its potential to combat asthma, which affects 20 million Brazilians.
Brazilian researchers have created a type of bread that could potentially prevent asthma, a respiratory condition that leads to approximately 350,000 hospital admissions annually in the SUS (Sistema Único de Saúde), the country’s public health system.
The formulation, for which a patent application has been filed in Brazil (BR1020210266465), is described in an article published in the journal Current Developments in Nutrition. It contains Saccharomyces cerevisiae UFMG A-905, a strain of brewer’s yeast with probiotic properties that has been shown to attenuate the symptoms of asthma in mice. Further trials involving human volunteers are still required.
One of the most common diseases in the world, asthma is increasingly frequent and affects some 20 million Brazilians, according to the database maintained by the Ministry of Health (DATASUS). It is characterized mainly by airway inflammation and hyperresponsiveness. Its exact causes are poorly understood, but it is known to be associated with environmental irritants, diet, and gut microbiota, among other factors.
Probiotics and Asthma
Asthmatic patients can benefit from ingestion of probiotics thanks to the link with gut microbiota. These beneficial bacteria are typically administered on their own or blended with dairy products such as milk, yogurt and kefir, but nothing prevents the use of other vehicles, which is advisable for patients who suffer from lactose intolerance or milk protein allergy.
In this study, which was funded by FAPESP, researchers at the University of São Paulo (USP) included S. cerevisiae UFMG A-905 in naturally fermented bread for the first time. Groups at the State University of Campinas (UNICAMP) and the Federal University of Minas Gerais (UFMG) collaborated on the project.
Researcher Ana Paula Carvalho (left) making dough enriched with microcapsules of S. cerevisiae UFMG A-905 (bottom right). Credit: Ana Paula Carvalho
To assess its potential, the researchers tested and compared three types of bread. The first was fermented with commercial yeast, the second with S. cerevisiae UFMG A-905, and the third with S. cerevisiae UFMG A-905 plus microcapsules containing live S. cerevisiae UFMG A-905.
“We added encapsulated live yeast in order to improve probiotic viability and activity at the high temperature reached during the baking process,” said Marcos de Carvalho Borges, the last author of the article and a professor in the Department of Clinical Medicine at the Ribeirão Preto Medical School (FMRP-USP). “Microcapsules protect bioactive and probiotic compounds, improving their stability, survival and bioavailability.”
Mice with asthma were fed the different types of bread for 27 days. At the end of the experiment, the mice fed S. cerevisiae UFMG A-905 bread displayed less airway inflammation and lower levels of asthma biomarkers (interleukins 5 and 13, or IL5 and IL13, which are proteins secreted by the immune system).
In mice fed the bread containing microencapsulated yeast, airway hyperresponsiveness and levels of IL17A, another biomarker of asthma, were also reduced. These results were similar to those of previous studies, confirming that live S. cerevisiae UFMG A-905 can help prevent asthma.
“We found that both types of bread fermented with S. cerevisiae UFMG A-905 prevented the development of asthma in the mice, which in conjunction with the results of other experiments shows that this yeast has highly consistent effects and appears genuinely capable of combating this respiratory disorder,” Borges said.
Next stage: clinical trial
While acknowledging the limitations of the study, such as not including bread fermented with commercial yeast plus microcapsules and not assessing the survival of S. cerevisiae UFMG A-905 microcapsules after baking, the scientists believe they can now take the next step, which will consist of developing a protocol for a clinical trial to observe the effects of the yeast on human beings.
“The product has significant potential,” Borges said. “Bread is a natural food consumed by almost everyone including children. It’s easily distributed and has a good half-life on the shelf.”
Reference: “A Functional Bread Fermented with Saccharomyces cerevisiae UFMG A-905 Prevents Allergic Asthma in Mice” by Ana Paula Carvalho Thiers Calazans, Thamires Melchiades Silva Milani, Ana Silvia Prata, Maria Teresa Pedrosa Silva Clerici, Jacques Robert Nicoli, Flaviano Santos Martins and Marcos Carvalho Borges, 22 March 2024, Current Developments in Nutrition.
DOI: 10.1016/j.cdnut.2024.102142
The study was also funded by the Ministry of Education’s Coordination for the Improvement of Higher Education Personnel (CAPES). The other co-authors of the article are Ana Paula Carvalho Thiers Calazans and Thamires Melchiades Silva Milani, researchers affiliated with FMRP-USP; Ana Silvia Prata and Maria Teresa Pedrosa Silva Clerici, professors at UNICAMP’s School of Food Engineering (FEA); and Jacques Robert Nicoli and Flaviano Santos Martins, professors at UFMG’s Institute of Biological Sciences (ICB).
